Dabigatran
Animal models found dabigatran reduced S. aureus abscess size and endocarditis measures. The trial dabigatran dose is 150 mg orally twice daily, with a 110 mg twice-daily option for selected older or higher-bleeding-risk patients where ava…
1 sources - 4 claims
Animal models found dabigatran reduced S. aureus abscess size and endocarditis measures. The trial dabigatran dose is 150 mg orally twice daily, with a 110 mg twice-daily option for selected older or higher-bleeding-risk patients where available. Dabigatran inhibits bacterial coagulase and staphylothrombin-mediated fibrin deposition. Dabigatran is approved for stroke prevention in non-valvular atrial fibrillation and for treatment and prevention of DVT and pulmonary embolism.